Sign in

NCT06477718Completed

Genomic Signatures for Patients With Initially Unresectable Colorectal Liver Metastases

Diverse Genomic Signatures Predict Resection Conversion and Survival Outcomes in Patients With Initially Unresectable Colorectal Liver Metastases

Source: ClinicalTrials.gov · Last updated 27 Jun 2024

Brief summary (registry, in English)

A retrospective cohort of 286 patients with synchronous CRLM underwent conversion therapies based on next-generation sequencing (NGS) results. All cases were categorized into a successful conversion therapy group (SCTG) if they achieved no evidence of disease (NED) status through surgery after conversion therapy, and a failed conversion therapy group (FCTG) otherwise. Clinical risk factors and genomic mutations were analyzed for association with conversion therapy outcomes and survival.

Status (registry)
Completed
Study type
Observational
Enrollment
286 (actual)
First submitted
22 Jun 2024
Start date
1 Jan 2016
Primary completion date
1 Dec 2018
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
NCT number
NCT06477718

What you commit to

  • Study type: Observational
  • Participants enrolled: 286
  • From 1 Jan 2016 to the primary completion date, 1 Dec 2018
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients were excluded if they: i) could not tolerate a full course of systemic therapy; ii) had a history of other malignancies; iii) had previously undergone cancer treatment; or iv) Patients who were not rendered disease-free at time of hepatic resection (i.e., primary intact, unresected extrahepatic disease, or gross \[R2\] residual hepatic disease) were excluded.

Who the study is looking for

  • At diagnosis, all patients met the criteria for preoperative conversion therapy, with a Cancer Recurrence Score (CRS) of ≥3

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.